 |
|
常見(jiàn)的血液腫瘤主要包括各類白血病、多發(fā)性脊髓瘤以及惡性淋巴瘤。急性白血病占常見(jiàn)惡性腫瘤的第八位，淋巴瘤也是在前十位，并且發(fā)病率逐年升高，多發(fā)性骨髓瘤的整個(gè)發(fā)病率在血液惡性腫瘤里面占10%。
以下產(chǎn)品可用于多種常見(jiàn)血液腫瘤研究，急性淋巴細(xì)胞白血病（Acute Lymphoblastic Leukemia (ALL)是一種起源于淋巴細(xì)胞的B系或T系細(xì)胞在骨髓內(nèi)異常增生的惡性腫瘤疾病。異常增生的原始細(xì)胞可在骨髓聚集并抑制正常造血功能，同時(shí)也可侵及骨髓外的組織，如腦膜、淋巴結(jié)、性腺、肝等。急性髓細(xì)胞白血病(acute myelocytic leukemia，AML)包括所有非淋巴細(xì)胞來(lái)源的急性白血病，是多能干細(xì)胞或已輕度分化的前體細(xì)胞核型發(fā)生突變所形成的一類疾病是造血系統(tǒng)的克隆性惡性疾病。淋巴瘤（Lymphoma）是起源于淋巴造血系統(tǒng)的惡性腫瘤，主要表現(xiàn)為無(wú)痛性淋巴結(jié)腫大，肝脾腫大。
相關(guān)產(chǎn)品列表： |
|
急性淋巴細(xì)胞白血病相關(guān)抗體 |
|
Antibody |
Catalog No. |
Host |
Clone |
Reactivity |
Tested Application/s |
|
CD3 |
NBP2-25186 |
Ms |
OKT3 |
Hu |
FLOW |
|
CD19 |
NBP2-25196 |
Ms |
CD19 |
Hu |
FLOW, IHC |
|
IL2RA/CD25 |
NBP2-27425 |
Rt |
PC61 |
Ms |
FLOW |
|
CD44 |
NBP1-47386 |
Ms |
8E2F3 |
Hu, Ms, Ca, Rb, Eq |
WB, ELISA, FLOW, ICC/IF, IHC, IHC-P |
|
Notch-1 |
NB100-78486 |
Ms |
mN1A |
Hu, Ms |
WB, FLOW, ICC/IF, IHC, IHC-P, IP | |
|
急性髓細(xì)胞樣白血病相關(guān)抗體 |
|
Antibody |
Catalog No. |
Host |
Clone |
Reactivity |
Tested Application/s |
|
c-Kit |
NB100-77477 |
Rt |
2B8 |
Hu, Ms |
FLOW, IHC, IHC-Fr, IP |
|
ETV6/Tel |
NBP1-80695 |
Rb |
poly |
Hu, Rt |
WB, ICC/IF, IHC, IHC-P |
|
Flt3/CD135 |
NBP1-43352 |
Rt |
A2F10 |
Ms |
FLOW, Func, IP |
|
Nucleophosmin |
NB110-61646 |
Rb |
poly |
Hu, Ms |
WB, FLOW, ICC/IF, IHC, IHC-P, IP |
|
RUNX1 |
NB100-2044 |
Rb |
poly |
Hu, Ms |
WB | |
|
淋巴瘤相關(guān)抗體 |
|
Antibody |
Catalog No. |
Host |
Clone |
Reactivity |
Tested Application/s |
|
Bcl2 |
NB100-56098 |
Rb |
poly |
Hu, Bv, Ca, Fe |
WB, IHC, IHC-P, IP |
|
CD5 |
NBP2-02690 |
Ms |
7A7 |
Hu |
WB, FLOW, ICC/IF, IHC, IHC-P |
|
CD10 |
NBP1-47356 |
Ms |
2A1H5E1 |
Hu |
WB, ELISA, ICC/IF, IHC, IHC-P |
|
CD15 |
NBP1-28441 |
Ms |
28 |
Hu |
FLOW, IHC, IHC-Fr, IP |
|
CD30 |
NBP2-29425 |
Ms |
CD30/412 |
Hu |
ELISA, FLOW, ICC/IF, IHC-Fr, IHC-P | |
|
多發(fā)性骨髓瘤相關(guān)抗體 |
|
Antibody |
Catalog No. |
Host |
Clone |
Reactivity |
Tested Application/s |
|
beta 2 microglobulin |
NB500-317 |
Ms |
B2M-01 |
Hu |
WB, ELISA, FLOW, IHC, IHC-P, IP, RIA |
|
CD38 |
NBP2-25250 |
Ms |
1G7F4 |
Hu, Ms |
WB, IHC, IHC-P |
|
CD56 + NCAM-1 |
NBP2-15184 |
Ms |
123C3 |
Hu, Rt, Ze |
WB, ELISA, FLOW, ICC/IF, IHC-Fr, IHC-P, IP |
|
IL-6 |
NB600-1131 |
Rb |
poly |
Hu, Ms, Rt |
WB, ELISA, ICC/IF, IHC, IHC-P, IP |
|
Syndecan 1 |
NBP1-54523 |
Ms |
MI15 |
Hu |
FLOW, ICC/IF, IHC, IHC-P | |
|
|
|
CD3 NBP02-25186 |
CD10 NBP1-47356 |
IL-6 NB600-1131 |
|
| 關(guān)注Novus疾病研究（http://www.novusbio.com/Hematological-Cancers ）查詢更多與血液腫瘤相關(guān)的基因、通路、文獻(xiàn)及產(chǎn)品等信息。 |
